Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.

Background: Tazemetostat, the first enhancer of zeste homolog 2 (EZH2) inhibitor approved by the U.S. Food and Drug Administration, has shown efficacy in a global population with relapsed or refractory (R/R) follicular lymphoma (FL).

Intensive care unit outcomes and prognostic factors of esophageal cancer: A cross-sectional study in Chinese cancer-specialized hospitals.

Background: Esophageal cancer patients had the highest intensive care unit (ICU) admitted rate in cancer patients. But their prognosis and evaluation methods were rarely studied.

Aim: To depict the short-term mortality outcome and identify the potential prognostic factors of esophageal cancer patients admitted into ICU.

First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial.

Sacituzumab tirumotecan (sac-TMT, also known as MK-2870 or SKB264) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2. We report the initial findings from the ongoing phase 2 OptiTROP-Lung01 study, evaluating the combination of sac-TMT and tagitanlimab (KL-A167), an anti-PD-L1 antibody, as first-line therapy in patients with advanced or metastatic non-small-cell lung cancer who lack actionable genomic alterations (cohorts 1A and 1B). Cohort 1A received sac-TMT (5 mg kg, every 3 weeks) plus tagitanlimab (1,200 mg, every 3 weeks) in each 3-week cycle, whereas cohort 1B was treated with sac-TMT (5 mg kg, every 2 weeks) plus tagitanlimab (900 mg, every 2 weeks) in each 4-week cycle, in a nonrandomized manner until disease progression or unacceptable toxicity.

Targeted therapy combined with immunotherapy trifluridine/tipiracil with bevacizumab as late-line therapy in metastatic colorectal cancer.

Background: Targeted therapy combined with anti-programmed cell death 1 immunotherapy (TP) and trifluridine/tipiracil (TAS-102) combined with bevacizumab (TB) are two common therapies for patients with late-line therapy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). However, it is still unclear which therapy can bring better prognosis.

Aim: To evaluate the effectiveness and safety of TP TB as the late-line regimen for MSS mCRC in the real world.

Innate Lymphoid Cells Are the Rheostat of Immune Response in the Kidney.

Kidney disease ranks as the seventh most significant and the third fastest-growing risk factor contributing to mortality globally. Innate lymphoid cells (ILCs) are tissue-resident immune cells that lack antigen-specific receptors and produce robust cytokines. ILCs play vital roles in infection, allergy, metabolic disorders, cancers, and tissue homeostasis.

Association of vitamin D receptor gene polymorphisms in gastrointestinal cancer: A systematic review and meta-analysis.

Background: Gastrointestinal cancers (GICs), encompassing malignancies of the esophagus, stomach, and colorectal regions, are among the most prevalent cancers worldwide. Given the inconsistent and heterogeneous findings across studies, this meta-analysis aims to comprehensively assess the association between vitamin D receptor (VDR) gene polymorphisms and the risk of GICs.

Methods: A systematic search was conducted in MEDLINE, Web of Science, Scopus, and Embase to identify relevant studies investigating the association between VDR polymorphisms and GIC risk.

Real world effectiveness of chemotherapy plus bevacizumab with immunotherapy in colorectal cancer.

Patients diagnosed with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) typically have an immunosuppressive tumor microenvironment, which leads to a low response rate when treated with immunotherapy. Some studies indicate that chemotherapy and anti-angiogenic therapy could potentially improve the responsiveness of these patients to immunotherapy. Therefore, this study is designed to assess the effectiveness and safety of combining chemotherapy with bevacizumab and anti-PD-1 immunotherapy as a second-line treatment option for MSS mCRC.

IMforte: A new starting point and new challenges.

The IMforte study demonstrated that maintenance treatment with atezolizumab plus lurbinectedin significantly improved progression-free survival and overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC). This phase 3 study is the first to report a positive result in first-line maintenance therapy for ES-SCLC, representing another milestone that is likely to establish a new standard of care for this condition.

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial.

We aimed to assess the tolerability and efficacy of finotonlimab (an anti-programmed cell death protein-1 antibody) in combination with SCT510, a bevacizumab biosimilar, versus sorafenib in unresectable advanced HCC. This randomized phase 2 and 3 study (ClinicalTrials.gov, NCT04560894; Chinadrugtrials.

Correlation between allergic diseases and lung cancer: a systematic review and meta-analysis.

Objectives: This meta-analysis aims to investigate the potential association between allergic diseases and lung cancer.

Methods: A systematic search was conducted in PubMed, Cochrane Library, Embase, and Web of Science databases up to October 8, 2024. Data analysis was performed using Stata 14.

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.

Introduction: Intravenous anticancer treatments present challenges for patients and healthcare professionals (HCPs), prompting the development of subcutaneous formulations. In the phase 3 PALOMA-3 study, subcutaneous amivantamab demonstrated noninferior pharmacokinetics and response rates versus intravenous amivantamab (both with lazertinib), with substantially faster administration, a 5-fold reduction in infusion-related reactions, reduced venous thromboembolism, and numerically prolonged survival.

Methods: Participants with EGFR-mutated NSCLC and progression on osimertinib and chemotherapy were randomized to subcutaneous (n = 206) or intravenous amivantamab (n = 212), plus lazertinib.

Application of sentinel lymph nodes biopsy tracers for breast cancer after neoadjuvant chemotherapy in China: A multicenter, real-world study.

The real-world application of tracers for axillary sentinel lymph node biopsy (SLNB) for breast cancer (BC) after neoadjuvant chemotherapy (NAC) in China was unknown. We analyzed the use of individual tracers or combinations and number of SLNs in patients with BC who underwent SLNB with or without axillary lymph node dissection (ALND) after NAC in 20 hospitals in ten years. A total of 1251 BC patients underwent SLNB or SLNB + ALND after NAC, including 853 (68.

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.

Introduction: Lazertinib is a central nervous system-penetrant, third-generation EGFR tyrosine kinase inhibitor (TKI) that was selected for combination with amivantamab due to its relatively low rates of wild-type EGFR toxicities. In the phase 3 MARIPOSA study, amivantamab plus lazertinib (amivantamab-lazertinib) significantly improved progression-free survival (PFS; p < 0.001) versus osimertinib in participants with treatment-naive EGFR-mutant advanced NSCLC.

Ultra-rapid meningeal metastasis in triple-negative breast cancer: A case report.

Introduction And Importance: Triple-negative breast cancer (TNBC) is highly invasive and poorly responsive to standard treatments, making it prone to brain metastasis, which exhibits significant intracranial invasiveness. But brain metastasis is extremely rare within one month after neoadjuvant therapy and standard modified radical surgery. Here, we report a case of a patient who, after completing neoadjuvant chemotherapy and achieving partial remission (PR), was diagnosed with brain metastasis one month post-surgery.

Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer.

Background: Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) is characterized by an immunosuppressive tumor microenvironment, leading to limited efficacy of immunotherapy in these patients. Clinical trial data suggest that chemotherapy and anti-angiogenic therapy may have the potential to enhance the response to immunotherapy in these patients. However, whether these research findings can be "replicated" in clinical practice still requires further validation through real-world studies.

Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database.

Introduction: Carboplatin is frequently employed in the treatment of non-small cell lung cancer (NSCLC), yet the real-world safety profile-including underrecognized adverse events (AEs) and subgroup-specific risk variations-remains incompletely understood. This study aims to systematically assess carboplatin-related AEs and explore demographic factors that may influence risk.

Methods: A retrospective analysis was performed using data from the FDA Adverse Event Reporting System (FAERS) spanning the first quarter of 2004 to the third quarter of 2024.

Application of deep learning based on convolutional neural network model in multimodal ultrasound diagnosis of unexplained cervical lymph node enlargement.

This study retrospectively analyzed the multimodal ultrasound features and clinical characteristics of 586 patients with unexplained cervical lymphadenopathy who were treated at three hospitals between October 2019 and December 2022. Statistically significant differences were found in the clinical and ultrasound features of all patients, including location, shape, margin, and color Doppler flow imaging (CDFI) (p<0.05).

Influence of migrasome-associated long noncoding RNAs on the immune microenvironment and prognosis in lung adenocarcinoma.

This study investigated the prognostic impact of migrasome-related long noncoding RNAs (lncRNAs) in lung adenocarcinoma (LUAD). We analyzed transcriptomic data from The Cancer Genome Atlas (TCGA) database, comprising 541 tumor samples and 59 normal tissue samples, to pinpoint key migrasome genes and related lncRNAs, using correlation analysis to detect those pertinent to patient outcomes. A risk score model based on 17 migrasome-related lncRNAs, constructed via univariate, LASSO, and multivariate Cox regression, was then validated in an independent dataset to ensure reliability.

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203).

Background: Lorlatinib is a potent third-generation ALK tyrosine kinase inhibitor (TKI). CROWN study demonstrated remarkable efficacy and manageable toxicity of first-line lorlatinib treatment for advanced non-small cell lung cancer (NSCLC) with ALK rearrangements. However, only 10 ALK-positive NSCLC patients were randomized to the lorlatinib group in China mainland.

Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer.

Background: Patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) typically exhibit an immunosuppressive tumor microenvironment and demonstrate a low response rate to immunotherapy. Reports suggest that chemotherapy and anti-angiogenic therapy may have the potential to enhance the response to immunotherapy in these patients. This study aims to evaluate the effectiveness and safety of chemotherapy combined with bevacizumab with or without anti-programmed death 1 (PD-1) immunotherapy as the second-line regimen for MSS mCRC.

Biomarkers and potential mechanisms of Chinese medicine compound (Chuanhong Zhongfeng Capsule) in the treatment of acute cerebral infarction.

Objective: Acute Cerebral Infarction (ACI) is characterized by high disability and recurrence rates, posing a significant threat to public health. The Chuanhong Zhongfeng (CHZF) Capsule, developed by national medical master Jixue Ren, has been clinically proven to promote neurological function recovery, reduce disability rates, and improve long-term prognosis in patients with cerebral infarction. However, the specific targets and potential mechanisms of action remain unclear.

Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.

Introduction: Response Evaluation Criteria in Solid Tumors (RECIST) is the primary tool for assessing tumor response in solid tumors. Immunotherapy elicits unique response patterns, and assessment of their contribution to overall survival (OS) is of interest. We evaluated tumor size changes (TSC) for association with OS, evaluated whether deeper response had greater association with OS than the 30% RECIST cutoff, and quantified the contribution of objective response rate (ORR) and duration of response (DOR) to OS benefit using data from KEYNOTE-189 and KEYNOTE-407 examining first-line pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer (NSCLC).